
|Articles|October 1, 2003
Biologics Seek 'Equal Footing' to Current Therapy
New York - The safety and efficacy of the new biologic agents for psoriasis suggest a new treatment strategy that departs from the current stepwise approach, according to Craig L. Leonardi, M.D., clinical associate professor of dermatology, Saint Louis University School of Medicine in Missouri.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
3
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
4
Dermatology Conferences and Meetings Calendar: December 2025
5


















